The Nordic AML Group – LD-VenEx:
Phase II study of Azacitidine in combination with low dose Venetoclax in patients with Acute Myeloid Leukemia
(Including exploratory evaluation of ex vivo drug sensitivity and resistance screening)
Principal investigator: Mika Kontro
HUS Helsinki University Hospital, Comprehensive Cancer Center
